Axa’s Outlook Therapeutics OTLK Stock Holding History

Axa’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,251	Closed	-$315K	–	1253
2021 Q3	$315K	Sell	7,251 -8,364	-54%	-$404K	﹤0.01%	1141
2021 Q2	$778K	Sell	15,615 -5,085	-25%	-$236K	﹤0.01%	1047
2021 Q1	$931K	Buy	+20,700	New	+$793K	﹤0.01%	985

Other funds holding OTLK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Axa's OTLK Position: Q4 2021 in Review

Axa sold out of Outlook Therapeutics (OTLK) in Q4 2021, closing a stake of 7,251 shares — an estimated $315K sold.

Axa first reported a position in OTLK in Q1 2021 and held it in 3 quarters. The position peaked at $931K in Q1 2021. 70 funds tracked by Wall St. Rank hold OTLK as of Q4 2021.

Axa reported no remaining Outlook Therapeutics position as of Q4 2021 after selling out during the quarter.
Axa sold 7,251 Outlook Therapeutics shares in Q4 2021, an estimated $315K.
Axa first reported a position in Outlook Therapeutics in Q1 2021 and held it in 3 quarters.
Axa's Outlook Therapeutics position peaked at $931K in Q1 2021.
70 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2021.

Based on Axa's 13F filing for Q4 2021, filed 14 Feb 2022.